Haibu Medical has received a strategic investment of 50 million yuan from Boteng Co., enhancing business synergy.

On October 26, 2020, Boteng Co., Ltd. announced its plan to make a strategic investment of 50 million yuan in Haibu Pharmaceutical using its own funds. After the completion of this capital increase, Boteng Co., Ltd. will hold 16.67% of the shares in Haibu Pharmaceutical, becoming its second-largest shareholder. Founded in 2005, Boteng Co., Ltd. is a leading contract development and manufacturing organization (CDMO) in China, dedicated to providing customized research and production services for pharmaceutical intermediates and active pharmaceutical ingredients throughout the entire lifecycle from early clinical research to drug market launch for global pharmaceutical companies and new drug research institutions. Haibu Pharmaceutical and Boteng Co., Ltd. established a strategic partnership for the cooperative production of high-end active pharmaceutical ingredients in 2017. With this capital increase from Boteng Co., Ltd., both parties will further enhance their business synergy and improve Haibu Pharmaceutical's influence in the field of pharmaceutical research and development, as well as strengthen its service capabilities to customers.

Founded in 2005, Haibu Pharmaceutical is a high-tech enterprise focused on chemical drug research and development, primarily engaged in the R&D, related registration, and custom production of high-end active pharmaceutical ingredients and pharmaceutical intermediates, as well as drug formulation R&D, technology transfer, and technical services. Haibu Pharmaceutical has 15 years of experience in drug R&D project management and drug registration experience, collaborative development of active pharmaceutical ingredients and formulation technologies, along with long-term deep service experience for clients. To date, it has transferred technology to Chinese pharmaceutical companies over 100 times and has applied for more than 20 related invention patents in areas such as structural modification of small molecule chemical drugs, process route optimization innovation, challenging polymorphs, and process patents.

Since its establishment, Haibu Pharmaceutical has adhered to a business attitude of "honesty and trustworthiness; win-win cooperation," a research spirit of "seeking truth from facts; professionalism and dedication," maintaining a strategic layout focused on "innovation-driven change," committed to realizing the "Haibu dream" that adds happiness to life and brings hope to existence. "All past events are merely prologues; all future expectations are magnificent chapters." In the future, Haibu Pharmaceutical will continue to uphold its value propositions and beliefs while creating value for customers and society.

(Image source: Internet)